((lp0
VisWord
p1
aVcase
p2
aVstops
p3
aVstem
p4
acnltk.probability
FreqDist
p5
((dp6
S'concept'
p7
I1
sS'disease progression stag'
p8
I1
sS'consider'
p9
I5
sS'endpoint of'
p10
I1
sS'final visit'
p11
I1
sS'random'
p12
I2
sS'unique model'
p13
I1
sS'code'
p14
I1
sS'dbp'
p15
I3
sS'nifedipine-git'
p16
I1
sS'titration studi'
p17
I1
sS'ground'
p18
I1
sS'niacin'
p19
I1
sS'articl'
p20
I1
sS'double-blind studi'
p21
I1
sS'parametr'
p22
I1
sS'program'
p23
I2
sS'vasodilatori'
p24
I1
sS'relative comparison of th'
p25
I1
sS'treatment effect of'
p26
I2
sS'relative comparison of'
p27
I1
sS'clinical practic'
p28
I1
sS'practical quest'
p29
I1
sS'exercise capac'
p30
I1
sS'parallel groups tri'
p31
I1
sS'publishing industri'
p32
I1
sS'commercial computer softwar'
p33
I1
sS'of niacin'
p34
I2
sS'six-month'
p35
I1
sS'subfract'
p36
I1
sS'respond'
p37
I2
sS'prevent'
p38
I1
sS'titration study of omapatrilat'
p39
I1
sS'semi-observational studi'
p40
I1
sS'investig'
p41
I4
sS'imput'
p42
I2
sS'randomized subject'
p43
I2
sS'lipoprotein subfract'
p44
I1
sS'pmi'
p45
I5
sS'subject'
p46
I6
sS'statu'
p47
I3
sS'compar'
p48
I1
sS'ich-e9 guidelin'
p49
I1
sS'review'
p50
I2
sS'particip'
p51
I1
sS'clinical statu'
p52
I3
sS'abbrevi'
p53
I1
sS'on harmon'
p54
I1
sS'new'
p55
I1
sS'approach'
p56
I1
sS'locf last-observation-carried-forward'
p57
I1
sS'conventional last-observation-carried-forward'
p58
I1
sS'assumpt'
p59
I1
sS'kaplan-mei'
p60
I1
sS'numer'
p61
I1
sS'ciltexetil'
p62
I1
sS'locf for'
p63
I1
sS'semi-observational study imbed'
p64
I1
sS'cardiovascular death'
p65
I2
sS'study imbed'
p66
I1
sS'ventricular mass'
p67
I1
sS'drug'
p68
I1
sS'omapatrilat'
p69
I1
sS'trial'
p70
I14
sS'survey'
p71
I1
sS'new york heart association class'
p72
I1
sS'bp'
p73
I11
sS'studi'
p74
I17
sS'literatur'
p75
I1
sS'mirror image of th'
p76
I1
sS'cancer'
p77
I1
sS'guidelin'
p78
I1
sS'hydrochlorothiazid'
p79
I2
sS'study treat'
p80
I1
sS'subgroup pati'
p81
I1
sS'outcome-correlated baselin'
p82
I1
sS'study sampl'
p83
I1
sS'explanatory tri'
p84
I1
sS'pimobendan'
p85
I1
sS'association class iv'
p86
I1
sS'visit'
p87
I3
sS'systolic blood'
p88
I1
sS'imbed'
p89
I1
sS'mark'
p90
I1
sS'treat'
p91
I1
sS'pi'
p92
I1
sS'life'
p93
I1
sS'non-parametr'
p94
I1
sS'dropout'
p95
I1
sS'flaw'
p96
I1
sS'diastolic blood'
p97
I2
sS'protocol viol'
p98
I1
sS'lovastatin'
p99
I1
sS'verapamil-sr'
p100
I1
sS'examin'
p101
I1
sS'treatment effect of pimobendan'
p102
I1
sS'primary pre-specified analysis of exercis'
p103
I1
sS'parallel-design studi'
p104
I1
sS'endpoint'
p105
I7
sS'journal articl'
p106
I1
sS'histori'
p107
I1
sS'randomized tri'
p108
I1
sS'post-hoc'
p109
I1
sS'outcom'
p110
I1
sS'mirror image of'
p111
I1
sS'clinical studi'
p112
I1
sS'observ'
p113
I4
sS'practition'
p114
I3
sS'locf'
p115
I12
sS'medical publish'
p116
I1
sS'medical visit'
p117
I1
sS'registr'
p118
I1
sS'diabetes tri'
p119
I1
sS'calcul'
p120
I2
sS'iv'
p121
I1
sS'topic'
p122
I1
sS'terminal diseas'
p123
I1
sS'international confer'
p124
I1
sS'atorvastatin'
p125
I1
sS'ie'
p126
I1
sS'statistical literatur'
p127
I1
sS'endpoint of cardiovascular death'
p128
I1
sS'medic'
p129
I1
sS'negative studi'
p130
I1
sS'study therapi'
p131
I2
sS'research top'
p132
I1
sS'misconcept'
p133
I1
sS'popular practic'
p134
I1
sS'hypertens'
p135
I1
sS'time-point'
p136
I4
sS'post-therapy observ'
p137
I1
sS'multiple imput'
p138
I1
sS'mar'
p139
I1
sS'international conference on'
p140
I1
sS'mortal'
p141
I1
sS'tool'
p142
I1
sS'covari'
p143
I1
sS'primary endpoint'
p144
I1
sS'new york'
p145
I1
sS'harmon'
p146
I2
sS'attempt'
p147
I1
sS'practic'
p148
I2
sS'loss-to-follow-up'
p149
I1
sS'restrictive model'
p150
I1
sS'clinical trial practition'
p151
I2
sS'question mark'
p152
I1
sS'trial monitor'
p153
I1
sS'analytical studi'
p154
I1
sS'withdraw'
p155
I14
sS'abbreviations bp'
p156
I1
sS'model'
p157
I7
sS'partial imput'
p158
I1
sS'subgroup'
p159
I3
sS'protocol'
p160
I1
sS'multicent'
p161
I3
sS'intent to'
p162
I1
sS'dropout categori'
p163
I1
sS'collabor'
p164
I1
sS'candesartan ciltexetil'
p165
I1
sS'itt'
p166
I8
sS'death'
p167
I4
sS'monitor'
p168
I1
sS'pragmatic tri'
p169
I1
sS'treatment'
p170
I19
sS'exercis'
p171
I11
sS'within-subject vari'
p172
I1
sS'survey research'
p173
I1
sS'potential bia'
p174
I1
sS'atherogenic dyslipidemia'
p175
I1
sS'therapi'
p176
I2
sS'bia'
p177
I1
sS'introduct'
p178
I1
sS'titration study of'
p179
I1
sS'proper multiple imput'
p180
I1
sS'medical journal articl'
p181
I1
sS'study of omapatrilat'
p182
I1
sS'chronic heart'
p183
I1
sS'2i'
p184
I2
sS'treatment cod'
p185
I1
sS'study conclus'
p186
I1
sS'dyslipidemia'
p187
I1
sS'practical usag'
p188
I1
sS'intern'
p189
I1
sS'sampl'
p190
I1
sS'mirror'
p191
I1
sS'hemodynam'
p192
I1
sS'event'
p193
I1
sS'baselin'
p194
I1
sS'variabl'
p195
I3
sS'ich'
p196
I2
sS'york heart association class iv'
p197
I1
sS'research'
p198
I2
sS'categori'
p199
I1
sS'four-week'
p200
I1
sS'post-randomization stratif'
p201
I1
sS'patient'
p202
I3
sS'all-cause mort'
p203
I1
sS'prevention studi'
p204
I1
sS'usag'
p205
I1
sS'regression model'
p206
I3
sS'treatment effect of niacin'
p207
I1
sS'last-observation-carried-forward'
p208
I2
sS'stage'
p209
I1
sS'trial practition'
p210
I2
sS'review attempt'
p211
I1
sS'popular approach'
p212
I1
sS'cardiovascular ev'
p213
I1
sS'new york heart'
p214
I1
sS'to treat'
p215
I1
sS'industri'
p216
I1
sS'blood'
p217
I1
sS'softwar'
p218
I2
sS'misl'
p219
I1
sS'cancer histori'
p220
I1
sS'end-of-observ'
p221
I1
sS'rank'
p222
I1
sS'surviv'
p223
I3
sS'clinical tri'
p224
I8
sS'pre-specified model'
p225
I1
sS'open-label'
p226
I1
sS'question'
p227
I3
sS'capac'
p228
I1
sS'of omapatrilat'
p229
I1
sS'non-cardiovascular death'
p230
I1
sS'new york heart association class iv'
p231
I1
sS'termin'
p232
I1
sS'coronary vasodilatori'
p233
I1
sS'relative comparison of the treat'
p234
I1
sS'drug registr'
p235
I1
sS'hctz'
p236
I3
sS'essential hypertens'
p237
I1
sS'class iv'
p238
I1
sS'conclus'
p239
I1
sS'longitudinal studi'
p240
I1
sS'ground rul'
p241
I1
sS'enalapril'
p242
I1
sS'stratif'
p243
I1
sS'observational studi'
p244
I2
sS'primary response vari'
p245
I1
sS'medical journ'
p246
I1
sS'terminal disease progress'
p247
I1
sS'restrictive assumpt'
p248
I1
sS'statistical tool'
p249
I1
sS'progression stag'
p250
I1
sS'statistical concept'
p251
I1
sS'decreas'
p252
I1
sS'complet'
p253
I4
sS'medical publishing industri'
p254
I1
sS'proport'
p255
I1
sS'incompar'
p256
I1
sS'mmhg decreas'
p257
I1
sS'advic'
p258
I1
sS'technical review'
p259
I1
sS'double-blind'
p260
I3
sS'violat'
p261
I1
sS'denomin'
p262
I3
sS'mass'
p263
I1
sS'baseline covari'
p264
I1
sS'conference on harmon'
p265
I1
sS'medical investig'
p266
I2
sS'distribut'
p267
I1
sS'intent to treat'
p268
I1
sS'intent'
p269
I1
sS'statistical model'
p270
I1
sS'visit time-point'
p271
I1
sS'primary pre-specified analysis of'
p272
I1
sS'randomized pati'
p273
I2
sS'heart association class iv'
p274
I1
sS'mcar'
p275
I9
sS'rule'
p276
I1
sS'of pimobendan'
p277
I2
sS'of cardiovascular death'
p278
I1
sS'international conference on harmon'
p279
I1
sS'terminal disease progression stag'
p280
I1
sS'study med'
p281
I1
sS'new york heart associ'
p282
I1
stp283
Rp284
tp285
.